Type 1 Diabetes Mellitus
Conditions
Brief summary
Evaluating the use of Liraglutide in patients with Type 1 Diabetes.
Detailed description
This investigation will be a retrospective chart review of in type 1 diabetics who have been treated with liraglutide. The study will be conducted at Diabetes-Endocrinology Center of WNY at Millard Fillmore Hospital, affiliated to the State University of New York at Buffalo. Study Population: 40 patients with type 1 diabetes on treatment with either continuous subcutaneous insulin infusion (CSII; also known as insulin pump) or multiple (four or more) injections of insulin per day on continuous glucose monitoring system (CGMS) will be included in the study. These patients with type 1 diabetes have been treated with liraglutide in addition to insulin. The investigators would retrospectively review their charts to evaluate decreases in fasting, postprandial and the overall mean glucose concentrations. The investigators will compare the mean fasting, the mean weekly glucose and the standard deviation of weekly blood glucose concentrations as recorded by continuous glucose monitoring prior to and following one week and 12 weeks of treatment with liraglutide daily. In addition, the investigators will compare the time spent at glucose concentrations \>150 and 200mg/dl and \<70 and \<40 mg/dl. HbA1c levels before and after 12 weeks of treatment with liraglutide daily will be compared.
Interventions
DRUGLiraglutide
Liraglutide s/c 0.6mg once daily.
Sponsors
University at Buffalo
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Type 1 Diabetes Mellitus
Exclusion criteria
* Type 2 Diabetes Mellitus
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improved Blood Glucose comtrol in Type 1 Diabetes Patients with Liraglutide | 20 weeks |
Outcome results
None listed